Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.

Failed Dissolution Specifications: below specification limits for dissolution.

Recall #: D-1303-2022
Affected scope: 5677 bottles
Initiated: July 21, 2022

Compiled from official public sources by the publisher. · Updated September 2026

Teva Pharmaceuticals USA Inc recalled Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, R… - a moderate-severity action.

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, R… was recalled by Teva Pharmaceuticals USA Inc in August 10, 2022. Reason: Failed Dissolution Specifications: below specification limits for dissolution.. Check the official notice for the remedy. Verify recall #D-1303-2022 with the FDA Drug before acting.

The recall

Teva Pharmaceuticals USA Inc issued this moderate-severity FDA Drug recall-Failed Dissolution Specifications: below specification limits for dissolution..

Moderate
severity level: Class II
classification: August 10, 2022
reported

Sourced from official FDA Drug enforcement records. Verify recall #D-1303-2022 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.

Recall Insight

This recall's affected scope, documented in the Recall Profile below, stays within a single-region or limited-distribution footprint. Distribution scope (see Distribution below) directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.

Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.

Where this agency-classified recall sits among FDA Class I/II/III notices

Of 88,244 recalls with an agency hazard classification, 19,068 are high severity, 64,652 moderate, and 4,524 low. A further 16,179 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.

Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.

Product description

Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30-count bottles, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL USA 33314, USA, Distributed by: Actavis Pharma Inc., Parsippany, NJ 07054 USA; NDC 58544-692-30.

Reason for recall

Failed Dissolution Specifications: below specification limits for dissolution.

Recall Profile

Structured summary of the FDA Drug recall record
Attribute	Value
Agency	U.S. Food and Drug Administration
Severity class	Moderate (Class II)
Status	Terminated
Recall number	D-1303-2022
Date reported	August 10, 2022
Date initiated	July 21, 2022
Recalling firm	Teva Pharmaceuticals USA Inc
Firm location	Parsippany, NJ
Affected scope	5677 bottles
Distribution	Nationwide in the USA and Puerto Rico

Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.

What to do with this recall

Match your product against the recall record, then act on the agency remedy.

Check the recall number (D-1303-2022) and product description against the item you own. Search the archive
Confirm the current status with FDA Drug before acting, recall details can be updated.
Follow the documented remedy (refund, replacement, repair, or disposal) rather than general advice. What to do next

This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.

Frequently Asked Questions

What product was recalled? ▼

Why was this product recalled? ▼

Failed Dissolution Specifications: below specification limits for dissolution.

Which agency issued this recall? ▼

This recall was issued by the FDA Drug on August 10, 2022. Severity: Moderate. Recall number: D-1303-2022.

Where was the recalled product distributed? ▼

Distribution: Nationwide in the USA and Puerto Rico.

Should I stop using a recalled medication or medical device? ▼

Do not stop using a recalled medication or device without consulting your healthcare provider first, as abruptly discontinuing treatment could pose its own health risks. Your doctor can advise on alternatives or whether the recall applies to your specific product lot. Check the recall number and lot information against your product packaging.

Nationwide recalls with similar severity or category timing

Drug and device notices outside this firm and state, matched by severity timing and product category.

Similar severity · nearest report date

Same archive severity grade (Moderate), closest by report date among other firms and states.

Naftifine Hydrochloride Gel, USP 1%, pack… 2022-08-10 Amaranth Grain Organic, brand Natural Gro… 2022-08-10 Creamy Parmesan Risotto; Net Weight: 24 l… 2022-08-10 refrigerated BEVERAGE 1. PURE GREEN T… 2022-08-10

Similar Drugs & Medications · nearest report date

Same product category, closest by report date among other firms and states (deduped against the severity set).

SUSTANGO (Pendenadril Tytrate Blend) Caps… 2022-08-10 Triple Antibiotic Ointment, Bacitracin zi… 2022-08-17 Bisacodyl Suppositories, Fast Acting Stim… 2022-08-17 Naphcon A eye drops, Naphazoline HCl 0.02… 2022-08-17

Compare this recall with Kian Pee Wan Capsules, 30-count bottles → · All Drugs & Medications recalls

This recall: FDA Drug, reported August 10, 2022. Severity classes follow each agency's own taxonomy; related-recall context is computed across the full archive.

Methodology · Corrections · Archive as of August 2026